Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?-Reference-Cited by-同舟云学术

Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?

Published:2023-03-10 Issue:5 Volume:64 Page:907-909
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Robak Tadeusz¹^ORCID

Affiliation:

1. Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2188103

Reference15 articles.

1. Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages

2. Goede V, Fischer K, Dyer MJ, et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. In Proceedings from the European Hematology Association Annual Meeting; June 2018; Stockholm, Sweden (Abstract S151).

3. Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

4. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

5. Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia;Expert Opinion on Drug Metabolism & Toxicology;2023-09-02

2. The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies;Expert Opinion on Drug Discovery;2023-07-13

3. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study;Leukemia & Lymphoma;2023-04-16